<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885985</url>
  </required_header>
  <id_info>
    <org_study_id>ACOART BTK RENEW</org_study_id>
    <nct_id>NCT04885985</nct_id>
  </id_info>
  <brief_title>ACOART BTK RENEW：A Post Market Clinical Study</brief_title>
  <official_title>A Post Market Clinical Study to Evaluate the Safety and Efficacy of the Acotec Drug-coated Balloon in the Treatment of the Below-the-knee Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acotec Scientific Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acotec Scientific Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this prospective, multi-center, single arm study is to obtain further data&#xD;
      on the safety and performance of the Acotec Litos&amp;Tulip Drug-coated Balloon catheters in the&#xD;
      treatment of lesions in below-the-knee artery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>6 month</time_frame>
    <description>Primary patency rate is defined as freedom from clinically-driven target lesion revascularisation (CD-TLR) , restenosis as determined by duplex ultrasound (DUS) or digital subtraction angiography (DSA) or major target limb amputation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse event (MAE) rate</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as a composite rate of all-cause death, target limb major amputation and CD-TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency rate</measure>
    <time_frame>12 months,24 months,36 months,48 months ,60 months</time_frame>
    <description>Defined as freedom from clinically-driven target lesion revascularisation (CD-TLR) , restenosis as determined by duplex ultrasound (DUS) or digital subtraction angiography (DSA) or major target limb amputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major target limb amputation</measure>
    <time_frame>12 months,24 months,36 months,48 months ,60 months</time_frame>
    <description>A major adverse limb event is defined as above-ankle amputation of the treated limb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All-cause mortality</measure>
    <time_frame>12 months,24 months,36 months,48 months ,60 months</time_frame>
    <description>All-cause mortality at 12, 24, 36, 48, 60 months post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically-driven target vessel revascularization (CD-TVR)</measure>
    <time_frame>12 months,24 months,36 months,48 months ,60 months</time_frame>
    <description>Clinically-driven target vessel revascularization (CD-TVR) at 12, 24, 36, 48, 60 months post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically-driven target lesion revascularization (CD-TLR)</measure>
    <time_frame>12 months,24 months,36 months,48 months ,60 months</time_frame>
    <description>Clinically-driven target lesion revascularization (CD-TLR) at 12, 24, 36, 48, 60 months post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ulcer healing</measure>
    <time_frame>12 months,24 months,36 months,48 months ,60 months</time_frame>
    <description>Ulcer healed or not; if not, improving, stagnant,worsening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of distal embolization</measure>
    <time_frame>through procedure completion</time_frame>
    <description>Rate of distal embolization defined as occurrence significant distal embolization in target limb through the end of the procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">107</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>DEB catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use DEB catheter to treat the stenosis or occlusion in below popliteal artery of experimental arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DEB catheter</intervention_name>
    <description>Trade name of DEB catheter: AcoArt Tulip (0.018&quot;) or AcoArt Litos (0.014&quot;)</description>
    <arm_group_label>DEB catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age ≥18 years old and ≤75 years old&#xD;
&#xD;
          -  2. Rutherford clinical category classification：3,4 or 5&#xD;
&#xD;
          -  3. Significant stenosis (≥70%) or occlusions of de-novo or restenotic lesion(s)&#xD;
             located in below-the-knee arteries which distal bloodflow is patent.&#xD;
&#xD;
          -  4. Reference vessel diameter is between 2 mm and 4 mm&#xD;
&#xD;
          -  5. Subject has provided written informed consent prior to participation , understands&#xD;
             the purpose of this trail and agrees to comply with all protocol-specified&#xD;
             examinations and follow-up appointments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Plasma creatinine clearance rate &lt;30 mL/min&#xD;
&#xD;
          -  2. Acute vessel occlusion or acute thrombosis in target lesion&#xD;
&#xD;
          -  3. Planned amputation on the target limb&#xD;
&#xD;
          -  4. Subjects confined to bed that are completely non-ambulatory.&#xD;
&#xD;
          -  5. Thrombolytic therapy or surgical procedure on the target limb within 6 weeks prior&#xD;
             to enrollment.&#xD;
&#xD;
          -  6. Life expectancy &lt; 5 year.&#xD;
&#xD;
          -  7. Cumulative length of 100% occluded target lesion(s)&gt;150 mm&#xD;
&#xD;
          -  8. In-stent restenosis within the target lesion, or the distance between the target&#xD;
             lesions and the stent was less than 20 mm&#xD;
&#xD;
          -  9. History of stroke within 90 days prior to enrollment&#xD;
&#xD;
          -  10. Known allergy to contrast agents, antiplatelet, anticoagulant, or thrombolytic&#xD;
             therapy&#xD;
&#xD;
          -  11. Uncorrectable bleeding diathesis&#xD;
&#xD;
          -  12. The lesion of the inflow pathway cannot be identified due to the complete&#xD;
             occlusion of the P3 segment of the popliteal artery&#xD;
&#xD;
          -  13. Pregnant or breastfeeding female subjects&#xD;
&#xD;
          -  14. Ability to cross a guidewire through target lesion&#xD;
&#xD;
          -  15. Patients who have participated in clinical trials of other medical devices or&#xD;
             drugs during the same period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhuang Baixi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiyuan Hospital of China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhuang Baixi</last_name>
    <phone>010-62835122</phone>
    <email>zhuangbaixi@163.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

